Edison Talks- Interview with CEO of InMed Pharmaceuticals

Edison Talks- Interview with CEO of InMed Pharmaceuticals

00:00
00:00

In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO of InMed Pharmaceuticals, the Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Max and Eric discuss Cannabinol (CBN), the minor cannabinoid at the heart of InMed’s programs, why the company chose it and the advantages it may have over cannabiodiol (CBD) and tetrahydrocannabinol (THC).

01:32 Overview of InMed Pharmaceuticals 02:21 Introduction to Cannabinol (CBN), the cannabinoid at the heart of InMed’s epidermolysis bullosa (EB) and glaucoma programs 05:55 Is CBN psychoactive? 08:37 Why did InMed choose CBN for EB? 13:11 Can CBN be used for the treatment of glaucoma? 16:27 How does InMed source CBN? 19:13 Please describe the program in EB 26:31 What are the key upcoming milestones for InMed?

Edison Exhibits- Healthcare demand remains robust

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free